Graduated in Pharmacy and Biochemistry at the São Paulo University (1984), master (1989) and PhD (1993) degrees in Biological Sciences (Biochemistry) at São Paulo University. Associated Researcher at the Institute of Biomedical Science at São Paulo University (since 2021). Research Director and Head of the Tumor Biology and Biomarkers of the A.C.Camargo Cancer Center (2011-2021). Supervisor at the graduation program of Fundação Antonio Prudente (2001-2024). Past President of the Brazilian Society for Cell Biology, past member of the Council of the International Society for Neurochemistry (2010-2013) and Chair of the Committee for Aid and Education in Neurochemistry from the International Society for Neurochemistry (2011-2013). International Fellow of the Howard Hughes Medical Institute (2005-2010). Expertise in General Biology with main interest in cell biology and molecular biology. Primary research areas: tumor biology, biomarkers, cancer and prion diseases.Co-founder and CEO of Aljava Biotech, a startup that will develop a platform in functional precision oncology to identify the best treatment for each patient. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| El portero de las células |
| Comunicación interrumpida |
| Gatekeeper to the cells |
| Interrupted communication |
| Comunicación interrumpida |
| More itemsLess items |
| Choice of best medication for cancer treatment can be facilitated by predictive testing |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Cancer treatment is a global challenge, and the incidence rates in Brazil are expected to increase by 68% by 2040. The best estimate of cancer treatment costs in Brazil (SUS and supplementary health) published in 2018 showed that systemic treatment (chemotherapy) was around R$8 billion. The high resistance rate to standard-of-care medications is a significant limitation in treating advanc…
Cancer treatment is a major challenge in the world and, in Brazil, as in other middle-income countries (according to the World Bank), incidence rates are expected to increase by 68% by 2040. The estimate of direct costs for the treatment of cancer in Brazil (Supplementary Health and SUS) in 2020 was R$19 billion, of which R$7.8 billion were related to chemotherapy treatments. About 70% of…
This document describes an investment proposal to use the Institutional Technical Funding (RTI) granted by FAPESP in 2020 to AC Camargo Cancer Center. The International Research Center (CIPE) of AC Camargo Cancer Center provides core facilities and technical services to all researchers to carry out cutting-edge basic and translational research in Oncology. With the increasing number of pr…
(Only some records are available in English at this moment)
Renal cell carcinoma (RCC) is one of the ten most common types of tumors globally and has several histological subtypes with unique molecular signatures. Treatment of RCC is performed with partial or total nephrectomy for localized disease. However, part of the diagnoses occurs when the disease is in an advanced stage or when metastasis is present, resulting in resistance to systemic trea…
Renal cell carcinoma (RCC) represents about 90% of all renal malignancies and their causes are not established until the present moment. Its primary treatment consists of partial or total nephrectomy, but at the time of diagnosis 20% to 30% of the patients present metastasis and another 20% will experience recurrence and metastasis within a period of 1 to 3 years. Treatment for metastatic…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 30 / 24 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 60 / 16 | Completed scholarships in Brazil |
| 93 / 43 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ResearcherID
ORCID
Google Scholar Citations